Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Primary objective is to determine the effectiveness of the combination of bortezomib and
doxorubicin in patients with metastatic breast cancer. The trial format is a single arm Phase
II design wherein patients are treated with bortezomib IV on days 1, 4, 8, and 11 and with
doxorubicin IV on days 1 and 8 of a 21-day cycle.
Phase:
Phase 2
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborators:
Millennium Pharmaceuticals, Inc. National Cancer Institute (NCI)